US 11,884,937 B2
Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mRNA
John P. Cooke, Houston, TX (US); and Eduard Yakubov, Houston, TX (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Aug. 5, 2020, as Appl. No. 16/986,071.
Application 15/479,979 is a division of application No. 14/615,955, filed on Feb. 6, 2015, granted, now 9,738,873, issued on Aug. 22, 2017.
Application 16/986,071 is a continuation of application No. 15/479,979, filed on Apr. 5, 2017, granted, now 10,760,061.
Claims priority of provisional application 61/937,923, filed on Feb. 10, 2014.
Prior Publication US 2021/0130792 A1, May 6, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/074 (2010.01)
CPC C12N 5/0696 (2013.01) [C12N 2501/04 (2013.01); C12N 2501/60 (2013.01); C12N 2501/602 (2013.01); C12N 2501/603 (2013.01); C12N 2501/604 (2013.01); C12N 2501/606 (2013.01); C12N 2501/608 (2013.01); C12N 2501/90 (2013.01); C12N 2501/998 (2013.01); C12N 2506/09 (2013.01); C12N 2506/28 (2013.01)] 12 Claims
 
1. A method of nuclear reprogramming of mammalian somatic cells, the method comprising:
contacting a population of the mammalian somatic cells with:
an effective dose of an innate immune response activator; and
a population of modified mRNA (mmRNA), wherein at least 1% of the mmRNA population comprises 5′ triphosphate encoding a cocktail of reprogramming or transcriptional factors.